Treatment of Incidental Prostate Cancer by Active Surveillance: Results of the HAROW Study

Urol Int. 2015;95(2):209-15. doi: 10.1159/000431024. Epub 2015 May 30.

Abstract

Objective: To report on a cohort of patients with incidental prostate cancer (IPC) that was treated by an active surveillance (AS) protocol in the HAROW study.

Materials and methods: The HAROW study is an observational study on the management of localized prostate cancer in Germany. Treating urologists were reporting clinical parameters, information on therapy and clinical course of disease at 6-month intervals.

Results: In total, 3,169 patients were enrolled. In 224 patients were found an IPC and 104 (46%) of them were put on an AS protocol. The mean follow-up was 26.5 months. Tumor progression was noted in 16 patients. In 11 patients, AS was replaced by a definite intervention. In univariate and multivariate analyses, only PSA density correlated with progression.

Conclusion: This is the first prospective description of an IPC patient cohort on AS as part of an outcomes research study. AS was selected as a therapeutic strategy in nearly half of the patients (46%). Only a minor proportion (16%) displayed progression. Of the clinical parameters, only PSA density correlated with progression.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Disease Progression
  • Early Detection of Cancer / methods*
  • Follow-Up Studies
  • Germany
  • Hormones / therapeutic use
  • Humans
  • Incidental Findings
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prospective Studies
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatectomy
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Treatment Outcome

Substances

  • Hormones
  • Prostate-Specific Antigen